Replies to post #776891 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

"stream of requests" - "to try to help brain cancer patients" - "in the process of making the operational arrangements"
"The Company is also working on" - "The Company believes "

Absolutely nothing concrete, just more breadcrumbs and vague legal jargon. IMO
Q: If the compassionate care is so successful and effective, where are all the patient results over 10 years and where is the revenue it generated over 10 years?
Ans: Nowhere in any SEC filing or company press release. Are they curing GMB and keeping it a secret from the shareholders and the entire world?? 🤣

[Slave1]

Absolutely spot on Beartrap and thanks for pulling that language. That paragraph in the 10-K is a major signal that many seem to have missed.

It confirms NWBO has already begun building out distributed clinic capacity in London under the Specials framework and that these arrangements are explicitly tied to initial potential commercialization not just compassionate use.

This is not theoretical It is operational And it lines up perfectly with the broader strategy:

1. Sawston remains the licensed manufacturing hub.

2. Flaskworks is being positioned for modular control site designation.

3. SI 87 now law creates the legal bridge for Flaskworks to be integrated without triggering a new MAA.

4. The London clinics fill the last gap actual points of care for deployment.

For anyone asking Where is the infrastructure the answer is right here disclosed in plain text NWBO is quietly activating a full stack delivery system from GMP grade antigen input to automated manufacturing to distributed clinical endpoints.

And the best part is the 10-K makes clear this buildout was underway before SI-87 even came into force. That means the team was not waiting on regulators they were planning around what was coming and laying the tracks early.

Critics have argued there is no launch plan. But this language does not just hint at one it describes one. These clinics are not placeholders. They are the early commercial access layer.

If approval hits whether under Specials early access or post SI-87 rollout the machinery is already turning.

This paragraph might be the most important quiet disclosure in the entire filing. Appreciate you surfacing it.

Now here is something worth adding Back in February 2023. Linda Powers gave a formal briefing to the UK Parliament All Party Parliamentary Group for Brain Tumours. This was well before the MAA was filed and over a year before SI-87 was laid. The topic was regulatory modernization and improving access to innovative therapies including the real world barriers companies like NWBO face when trying to deploy personalized treatments. So yes Powers engagement was foundational. She was laying groundwork early well before most realized what was coming.

That brings us to July 23 SI-87 was laid before Parliament on June 17 but July 23 is when it comes fully into force. That distinction matters. Before July 23 MHRA could prepare and structure submissions around the new law After July 23 it can execute. That means it can legally designate Flaskworks as a control site without triggering a new MAA or Type II variation. The tools become real.

But that does not mean everything happens on July 23. It just means the final constraint is lifted. The next regulatory milestone is the CHM meetings on July 24 and 25 where decisions on advanced therapies can be reviewed endorsed or finalized. So the door unlocks on the 23rd but the formal step through may follow immediately after.

Now a quick word on IFR It is not the main strategy now but it still matters IFR can serve as a bridge a way to start treating patients while scale up is underway. Even if Flaskworks and Eden are approved the rollout will take time. You cannot manufacture 1000 devices overnight. That is where Advent artisanal method combined with IFR plays a role. It allows a small but real flow of patients to begin treatment legally and safely while the automation network comes online.

So yes IFR still has purpose. It is not obsolete. It is a stabilizing mechanism while the bigger platform activates.

Everything we are seeing from Powers early advocacy to the 10-K clinic disclosures to SI-87 legal trigger to the CHM meeting window fits together. It is a measured deliberate buildout of a commercial system that was never meant to flip on overnight. But we are now at the phase where pieces are locking into place.

And that is why this part of the 10-K matters so much. It is not just about Specials. It is about readiness. And we are seeing it.

[attilathehunt]

Good catch!!!
My scenario....
July 23rd - Si2025 No. 87 becomes effective and enforceable 
July 24th-25th -  Approved...It just so happens the 24th is my son's birthday and the 25th is my anniversary. 
NWBO receives confirmation from MHRA late in the day  UK time - early afternoon here.
NWBO issues PR Friday after close announcing approval....Word spreads over the weekend...demand builds...shorts scramble to raise funds...naked shorts go crazy...Stock opens on Monday at $3....Stock halted at 9:33 due to significant imbalance....Stock opens back up at $6...Stock halted again....Longs cheer, Shorts in panic mode...Stock opens back up at $10...Shorts are toast....Retail ban from buying...Share price goes to $25...The world eyes are focused on DCVax-L.... All the naysayers profoundly apologize to LP and company. LP is in demand for every talk show....LP appears on 60 minutes...
Exciting week this week as shorts stubble over themselves to cover since the realization of approval hits them square between the eyes. 
The long wait is over!!!

[ATLnsider]

beartrap12, NWBio stated that the primary purpose of the collaborations with private clinics, is to increase capacity for dedicated leukapheresis units in the UK.

It was not to increase DCVax-L manufacturing capacity outside of the Sawston Facility and the London lab: